Global Tacrolimus Market to Surpass US$9,380.2 Million by 2030

SEATTLE, June 17, 2022 /PRNewswire/ — According to Consistent market informationthe Global tacrolimus market is estimated at US$6,485.3 million in 2022 and should present a CAGR of 4.7% during the forecast period (2022-2030).

Key Trends and Analysis of the Global Tacrolimus Market:

The major players operating in the market are focusing on adopting inorganic growth strategies such as business deals in order to increase their market shares. For example, in January 2022Aequus Pharmaceuticals Inc., a growing specialty pharmaceutical company, announced that it has agreed to an extension of terms with Sandoz, a global leader in generic pharmaceuticals and biosimilars, for its tacrolimus promotional service agreement at immediate release to December 31, 2022. Aequus launched promotional efforts in Canada in 2016 for Sandoz’s generic tacrolimus.

Request a sample copy of this report @

Main market takeaways:

The Global tacrolimus market is expected to show a CAGR of 4.7% during the forecast period, due to increasing product approvals by regulatory bodies. For example, in November 2020Glenmark Pharmaceuticals Ltd., a global research-based pharmaceutical company, has obtained final approval from the United States Food and Drug Administration (US FDA) for Tacrolimus Capsules USP, 0.5mg, 1mg and 5mg, the generic version of Prograf Capsules, 0.5mg, 1mg and 5mg from Astellas Pharma US, Inc., a Japanese multinational pharmaceutical company.

Among the product types, tacrolimus injections segment is expected to lead the segment growth during the forecast period. Tacrolimus injection is used with other medicines to prevent rejection (attack of the transplanted organ by the recipient’s immune system) in people who have had kidney, liver, or heart transplants. Tacrolimus injection should only be used by people unable to take tacrolimus by mouth.

Based on applications, immunosuppression segment is expected to dominate the segment growth over the forecast period, owing to increase in research and development of tacrolimus by key players. For example, in September 2021TFF Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced top results from its Phase 1 clinical trial for tacrolimus inhalation powder in lung transplantation, showing a promising safety profile and demonstrating that levels Drug therapeutics can be achieved at low doses.

Key players operating in the global tacrolimus market include Novartis AG, Mylan NV, Astellas Pharma Inc., Dr. Reddy’s Laboratories Ltd., Pfizer Inc., Abbott, Senju Pharmaceutical Co. Ltd., Glenmark Pharmaceuticals Ltd., Lupine Limited and Vibcare Pharma Pvt. ltd.

Customization request @

Detailed segmentation:

Global tacrolimus market, by product type:

  • Tacrolimus capsules and tablets
  • Tacrolimus ointment
  • Tacrolimus Injection
  • Tacrolimus granules

Global Tacrolimus Market, By Application:

  • Immunosuppression
  • Dermatitis
  • Others

Global tacrolimus market, by end user:

  • Organ Transplant Centers
  • Hospitals
  • Clinics
  • Others

Global tacrolimus market, by region:

  • North America
  • Europe
    • By country:
      • UK
      • Germany
      • Italy
      • France
      • Spain
      • Russia
      • Rest of Europe
  • Asia Pacific
    • By country:
      • China
      • India
      • Japan
      • ASEAN
      • Australia
      • South Korea
      • Rest of Asia Pacific
  • Latin America
    • By country:
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
  • Middle East & Africa
    • By country:
      • GCC countries
      • Israel
      • South Africa
      • Rest of Middle East & Africa

Buy this full report now @

About Us:

Consistent market information is a global market intelligence and advisory organization focused on helping our plethora of clients achieve transformational growth by helping them make critical business decisions. We have our head office at Indiahaving a sales office in the financial capital of the world in the United States and sales advisers in UK and Japan. Our client base includes players from various industries in more than 57 countries around the world. We create value for our clients through our highly reliable and accurate reports. We are also committed to playing a leading role in providing insight in various post-COVID-19 sectors and to continuing to deliver measurable and sustainable results to our clients.

Contact us:

Mr Shah
Senior Client Partner – Business Development
Consistent market information

WE: +1-206-701-6702
UK: +44-020-8133-4027
Japan: +81-050-5539-1737
India: +91-848-285-0837
Follow us: LinkedIn | Twitter


SOURCE Consistent Market Information

About Larry Noble

Check Also

Stock to buy: This multibagger IT stock is top pick for November, brokerage sees 20% returns, buy

Outlook and stock returns INFO is one of the leading large cap IT companies in …